Company Filing History:
Years Active: 2014
Title: S R Wayne Chen: Innovator in Cardiac Therapy
Introduction
S R Wayne Chen is a notable inventor based in Calgary, Canada. He has made significant contributions to the field of cardiac therapy through his innovative research and development of novel pharmaceutical compounds.
Latest Patents
One of his key patents is titled "Ryanodine receptor inhibitors and methods relating thereto." This invention provides novel ryanodine receptor type 2 (RyR2) inhibitors and methods for their use in treating cardiac conditions. The RyR2 inhibitors assist in normalizing intracellular calcium homeostasis, which is crucial for heart function. In certain embodiments, these inhibitors are store-overload-induced Ca-release (SOICR) inhibitors that minimally inhibit or do not inhibit Ca-induced Ca-release (CICR), thereby offering beneficial effects in cardiac therapy. He holds 1 patent related to this groundbreaking work.
Career Highlights
S R Wayne Chen is associated with Uti Limited Partnership, where he continues to advance his research in cardiac therapies. His work has the potential to significantly impact the treatment of various cardiac conditions, improving patient outcomes.
Collaborations
Some of his notable coworkers include Thomas G Back and Dawei Jiang, who have collaborated with him on various projects related to cardiac health and innovative therapies.
Conclusion
S R Wayne Chen's contributions to the field of cardiac therapy through his innovative patents highlight his role as a leading inventor in this critical area of medicine. His work continues to pave the way for advancements in treatment options for cardiac conditions.